Literature DB >> 19997085

ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease.

D J Stone1, C Molony, C Suver, E E Schadt, W Z Potter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19997085     DOI： 10.1038/tpj.2009.58

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


× No keyword cloud information.
  8 in total

1.  Apolipoprotein E epsilon 4 allele is associated with ventricular expansion rate and surface morphology in dementia and normal aging.

Authors:  Florence F Roussotte; Boris A Gutman; Sarah K Madsen; John B Colby; Katherine L Narr; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2013-12-05       Impact factor: 4.673

2.  Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer's disease.

Authors:  Alberto Serrano-Pozo; Zhaozhi Li; Ayush Noori; Huong N Nguyen; Aziz Mezlini; Liang Li; Eloise Hudry; Rosemary J Jackson; Bradley T Hyman; Sudeshna Das
Journal:  Nat Aging       Date:  2021-10-11

Review 3.  Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.

Authors:  Ranjan Duara; Warren Barker
Journal:  Neurotherapeutics       Date:  2022-01-27       Impact factor: 6.088

4.  Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.

Authors:  Richard E Kennedy; Gary R Cutter; Lon S Schneider
Journal:  Alzheimers Dement       Date:  2013-05-25       Impact factor: 21.566

5.  Characterizing Clinical and Neuropathological Traits of APOE Haplotypes in African Americans and Europeans.

Authors:  Aziz M Mezlini; Colin Magdamo; Emily Merrill; Lori B Chibnik; Deborah L Blacker; Bradley T Hyman; Sudeshna Das
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Molecular insights into the pathogenesis of Alzheimer's disease and its relationship to normal aging.

Authors:  Alexei A Podtelezhnikov; Keith Q Tanis; Michael Nebozhyn; William J Ray; David J Stone; Andrey P Loboda
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

Review 7.  Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.

Authors:  Li Shen; Paul M Thompson; Steven G Potkin; Lars Bertram; Lindsay A Farrer; Tatiana M Foroud; Robert C Green; Xiaolan Hu; Matthew J Huentelman; Sungeun Kim; John S K Kauwe; Qingqin Li; Enchi Liu; Fabio Macciardi; Jason H Moore; Leanne Munsie; Kwangsik Nho; Vijay K Ramanan; Shannon L Risacher; David J Stone; Shanker Swaminathan; Arthur W Toga; Michael W Weiner; Andrew J Saykin
Journal:  Brain Imaging Behav       Date:  2014-06       Impact factor: 3.978

8.  Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease.

Authors:  Mike A Nalls; Ziv Gan-Or; Hampton Leonard; Cornelis Blauwendraat; Lynne Krohn; Faraz Faghri; Hirotaka Iwaki; Glen Ferguson; Aaron G Day-Williams; David J Stone; Andrew B Singleton
Journal:  J Med Genet       Date:  2019-11-29       Impact factor: 6.318
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.